Reportage from AHA 2023
Small apo(a) isoform expression could be an important risk predictor of worse short term surgical outcomes after lower extremity revascularisation. This is the conclusion of researchers who related apoA size to revascularisation outcomes in 25 patients with symptomatic peripheral arterial disease (PAD).
Changes in Lp(a) level over time, recorded in placebo-treated individuals in the Phase 2 OCEAN(a)-DOSE trial, suggest that once-in-a-lifetime measurement of Lp(a) may not be sufficient for identifying at-risk individuals in need of treatment. Current American College of Cardiology (ACC) guidelines recommend once-in-a-lifetime Lp(a) measurement, while European Atherosclerosis Society consensus guidance supports Lp(a) testing at least once in adults.
A single dose of the short interfering RNA, lepodisiran (608 mg s.c.) reduced serum Lp(a) by 94% at 48 weeks follow up in a Phase 1 dose ranging study. Lepodisiran, which targets hepatic synthesis of apolipoprotein(a), a key component needed for assembly of Lp(a) particles, was well tolerated.
